Tilray Brands TodayTLRYTilray Brands$1.73 -0.12 (-6.49%) 52-Week Range$0.35▼$1.86Price Target$1.94Add to WatchlistThe stock market was jolted into action on Sept. 29 as shares of Tilray Brands NASDAQ: TLRY staged a monumental rally, closing the session with a gain of over 60% at $1.85 per share. The move was backed by a surge in trading volume, with more than 371 million shares changing hands, a figure over eight times its daily average of 44.65 million. Such a dramatic spike, triggered by external politic ...

Morsa Images/DigitalVision via Getty Images Listen below or on the go on Apple Podcasts and Spotify Cannabis stocks rally after Trump posts video touting CBD use for senior healthcare. (00:25) YouTube (GOOG) (GOOGL) to pay Trump $24.5M for suspending account after Capitol riot. (02:01) McDonald's (MCD) bets on Monopoly game to lure in loyalty members. (03:15) This is an abridged transcript. Cannabis stocks moved sharply higher on Monday after President Trump publicly endorsed the use of cannabidiol ( ...

Aurora Cannabis Inc (NASDAQ: ACB) rallied more than 25% this morning after President Trump endorsed cannabidiol (CBD) as potential breakthrough in senior healthcare. In a social media post over the we... ...

Group 1 - Alan Brochstein is a pioneer in the cannabis investment sector, having focused exclusively on this industry since 2007 [1] - He founded AB Analytical Services to provide independent consulting to registered investment advisors [1] - Brochstein is the managing partner of New Cannabis Ventures, which has been a key provider of financial information in the cannabis industry since 2015 [1] Group 2 - Alan has led the investing group 420 Investor since 2013, which focuses on publicly-traded cannabis stocks [2] - The group moved to Seeking Alpha in 2023 and covers 20 stocks, providing investment news, earnings report previews, and post-report analyses [2] - Features of the 420 Investor group include a model portfolio, 10 weekly videos with chart analysis, 3 weekly summary pieces, a monthly newsletter, and a chat for questions [2]

A study conducted in Europe advanced arguments for marijuana law reform around the world.Whenever there's news about potential marijuana legalization anywhere in the world -- or at least some measure of decriminalization -- the few publicly traded pot companies tend to benefit. This was the case on Tuesday with big multistate operator Curaleaf (CURLF 4.90%), as a new study undertaken on the other side of the world illustrated the benefits of making the drug legal. The company's share price was up by nearly ...

Financial Data and Key Metrics Changes - Total revenue for fiscal year 2025 declined from $151.9 million to $127.5 million, a decrease of $24.4 million compared to fiscal year 2024 [12] - Gross profit decreased to $22.7 million from $29.8 million year-over-year [13] - Gross margins were 17.8% for fiscal year 2025, down from 19.6% in fiscal 2024 [14] - Net loss was $39.2 million compared to $40.8 million in fiscal 2024 [15] - Cash held at June 30, 2025, was $24.4 million, a reduction of $10.7 million versus the previous year [15] Business Line Data and Key Metrics Changes - The company shifted focus from the cannabis sector to the higher-value nicotine sector, resulting in a decline in cannabis revenue [4][11] - The company reduced net accounts receivable by over 21% year-over-year, marking the first decline in history [6] - General and administrative expenses decreased from $7.6 million in Q3 2025 to $6.7 million in Q4 2025 [7] Market Data and Key Metrics Changes - European revenue increased to approximately $74.1 million, up 13.6% from $65.3 million in the previous year [13] - North American revenue dropped to approximately $32.6 million from $63.1 million, primarily due to the strategic pivot away from cannabis [13] - Revenue from Asia Pacific totaled approximately $12.3 million, down from $17.6 million in the previous year [13] - Revenue from other countries increased to $8.5 million, up from $6 million in fiscal 2024 [13] Company Strategy and Development Direction - The company is investing in manufacturing capabilities in Malaysia, planning to scale production from six lines to up to 80 lines [5] - Focus on building sustainable long-term partnerships in the cannabis sector rather than pursuing short-term volume gains [6] - The company is advancing regulatory initiatives, including PMPA activities for its devices, which could transform the regulatory landscape for nicotine delivery systems [9][10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the ongoing challenges in the cannabis industry due to cash flow issues and the lack of federal legalization [30] - The company is optimistic about its pivot to the nicotine sector, expecting it to lead to stronger and more sustainable growth [11] - Management highlighted the potential of breakthrough technologies like ICE-TECH and GMASH to reshape industry standards [18] Other Important Information - The company undertook significant cost optimization measures, achieving estimated annual savings of $10.2 million [8] - The appointment of Jay Yu as the new Chief Financial Officer reflects the company's commitment to strong financial stewardship [10] Q&A Session Summary Question: Key milestones for age gating technology approval - Management indicated that the FDA accepted the component PMPA application within four weeks, which is unprecedented [22] - The next step is the issuance of a deficiency letter, which could take anywhere from three months to over a year [23] Question: Approval timelines in other markets - Management expressed optimism about potential approvals in two unnamed countries that are moving quickly with the technology [25] Question: Intellectual property protections for age verification technology - The company has filed patents in multiple regions, emphasizing the strength of its IP defensibility [27] Question: Details on the $22 million provision for receivables - The provision was a cumulative effect from all customers rather than being tied to a single client [33] Question: Future of cannabis revenue - Management stated that Q4 2025 cannabis revenue is expected to be the bottom, with new customer acquisition and product development underway [45]

Core Viewpoint - Tilray Brands presents a compelling investment opportunity following a 42% stock surge driven by regulatory optimism regarding marijuana reclassification [2][9] Regulatory Catalyst - The potential reclassification of cannabis from Schedule I to Schedule III could significantly benefit cannabis firms, including Tilray [3] - This change would alleviate tax burdens, enhance investment access, and facilitate market expansion [4] Financial Performance Assessment - Tilray has demonstrated strong revenue growth, with a 10.8% average growth over three years, surpassing the S&P 500's 5.7% [5] - Recent revenue growth of 11.2% from $743 million to $827 million is double the broader market's 5.0% growth [5] Profitability Challenges - The company faces significant operational inefficiencies, with an operating margin of -12.8% and a net income margin of -114.4% [6] - The operating cash flow margin stands at -6.2%, indicating fundamental operational issues [6] Balance Sheet Strength - Tilray maintains a debt-to-equity ratio of 36.1%, higher than the S&P 500's 21.8%, but still manageable [7] - Cash reserves of $248 million provide liquidity, though a 7.3% cash-to-assets ratio suggests limited financial flexibility [7] Valuation Attractive - Tilray's price-to-sales ratio of 1.2x is significantly lower than the S&P 500's 3.2x, indicating substantial undervaluation [7] - The current valuation is well below the stock's average price-to-sales ratio of 4.3x over the past five years [7] Investment Verdict - Tilray is characterized as a speculative investment with high reward potential due to prospective regulatory changes [9] - The anticipated reclassification could relieve tax burdens and attract institutional investments, enhancing Tilray's valuation [10] Bear Case - Ongoing operational challenges and market volatility present considerable downside risks if significant policy shifts do not occur [11]

Market Overview - The US stock market is experiencing fluctuations near historical highs, with the S&P 500 index dropping 0.25% to 6373.45 points, the Nasdaq down 0.3% to 21385.4 points, and the Dow Jones down 0.45% to 43975.09 points [1][3] Economic Indicators - The upcoming US July CPI report is seen as a catalyst for market sentiment, with predictions that if the core CPI month-on-month growth is below 0.25%, the S&P 500 could rise by 1.5%-2%, while exceeding 0.4% could lead to a drop of 2%-2.75% [3] Investor Sentiment - A monthly survey by Bank of America indicates that approximately 91% of respondents believe US stocks are overvalued, marking the highest level since the survey began in 2001 [3] Sector Performance - The lithium sector saw significant gains due to production halt news from a project under CATL, with companies like American Lithium up 9.32% and Sigma Lithium up 22.79% [3] - AI application stocks faced declines, with C3.ai dropping 25.58% due to disappointing sales performance attributed to organizational restructuring and health issues of the CEO [4] - Another AI stock, BigBear.ai, also reported weaker-than-expected earnings, leading to a nearly 30% drop in its stock price [5] - Cannabis stocks experienced notable movements, with Tilray Brands rising 41.82% and Canopy Growth up 26.40% due to policy rumors [6] - Chocolate producer Hershey's stock fell 4.8% amid rising cocoa futures [7] Notable Stock Movements - Major tech stocks showed mixed results, with Apple down 0.83%, Microsoft down 0.05%, and Tesla up 2.85% [8] - Chinese concept stocks had a varied performance, with Alibaba down 1.43% and NIO up 1.45% [8]

Core Viewpoint - Trump's consideration of reclassifying cannabis to a lower danger level has led to a significant surge in cannabis stocks, indicating potential positive changes for the industry [1]. Group 1: Market Reaction - Cannabis-related stocks experienced strong performance on Monday, with Canopy Growth rising over 26%, Tilray Brands soaring more than 41%, and Cronos Group jumping over 14% to reach a 52-week high [1][2]. - Many cannabis stocks are currently priced below $1 per share, meaning small price changes can lead to substantial percentage increases [2]. Group 2: Regulatory Changes - Under current U.S. federal law, cannabis is classified as a Schedule I controlled substance, similar to cocaine [3]. - Discussions have focused on reclassifying cannabis to Schedule III, which includes steroids and products containing codeine [3]. - Tilray's CEO, Irwin Simon, anticipates that the reclassification process may take about a year, but Trump's public discussion has generated optimism within the industry [3][4]. Group 3: Political Support - Tim Seymour noted that the change in cannabis classification appears to have bipartisan support, suggesting a favorable environment for investment in the sector [5]. - Trump's involvement is seen as a potential catalyst for change, although he cannot unilaterally reclassify the drug [6][7].

Core Viewpoint - Trump's consideration of reclassifying cannabis to a lower danger level has led to a significant surge in cannabis stocks, indicating potential positive changes for the industry [1]. Group 1: Market Impact - Cannabis stocks experienced substantial gains on Monday, with Canopy Growth rising over 26%, Tilray Brands soaring more than 41%, and Cronos Group jumping over 14% to reach a 52-week high [1][2]. - The cannabis market is valued at approximately $80 billion, and a reclassification from Schedule I to Schedule III could be a "game changer" for the industry, allowing for different tax regulations and increased investment interest [1][4]. Group 2: Regulatory Changes - Currently, cannabis is classified as a Schedule I controlled substance under U.S. federal law, placing it in the same category as cocaine [3]. - Discussions have primarily focused on reclassifying cannabis to Schedule III, which includes substances like steroids and Tylenol with codeine [4]. - The reclassification process is expected to take about a year, as indicated by Tilray's CEO, who expressed optimism due to Trump's public discussion of the matter [4]. Group 3: Political Support - The potential change in cannabis classification appears to have bipartisan support, which could facilitate investment opportunities in the sector [4]. - Tim Seymour highlighted that now may be an advantageous time for investment in the cannabis industry, as institutional capital may not yet be fully engaged [4]. Group 4: Limitations of Authority - Despite Trump's support, he does not have the unilateral power to reclassify cannabis, as the authority lies with the Attorney General, who typically delegates this responsibility to the Drug Enforcement Administration [5].